Hamacher Resource Group celebrates four employees, each with 25 years of service
WAUKESHA, Wis. — Hamacher Resource Group on Wednesday honored four employees that are celebrating 25 years with the company this year: Cindy Eichstaedt, data entry assistant; Todd Marshall, network administrator; Kat Fronek, national account manager; and Steve Brester, information technology manager.
“We recognize how special it is to have employees reach this milestone with a company, and we are fortunate to have this depth of experience on our team,” stated Dawn Vogelsang, HRG president and leader of the owners group.
The four have been with the company almost as long as the 32 years that HRG has been in business, the company stated.
Fronek and Eichstaedt have worked in various roles in multiple departments since they started at the company, while Brester and Marshall’s roles have evolved as HRG’s IT department grew from a single mid-range computer to an extensive network, including numerous servers, desktop and remote users, as well as PC, Web and mid-range developers.
Brester and Fronek are part of the HRG owners group. The combined experience of the eight owners totals an impressive 173 years. “This kind of longevity and experience is a differentiator for HRG, as well as a competitive advantage in the health, beauty and wellness market space,” Vogelsang said. “It really is exceptional to have a management team so deeply ingrained in the industry, supported by associates who are equally passionate and committed to providing solutions.”
Bayer, Onyx seek approval for gastrointestinal tumor drug
WAYNE, N.J. — Bayer HealthCare and Onyx Pharmaceuticals are seeking approval for a new drug to treat tumors of the gut, the companies said.
Bayer and Onyx announced the submission to the Food and Drug Administration of an application seeking approval for regorafenib in patients with gastrointestinal stromal tumors, or GIST. Bayer developed the drug and formed a partnership with Onyx in 2011, whereby Onyx will receive a royalty on future global net sales of the drug in cancer-related indications. Both companies will promote the drug in the United States.
"The submission of regorafenib for the treatment of GIST marks an important milestone for Bayer, bringing us one step closer to potentially addressing a significant medical need for patients with this rare but aggressive disease," Bayer HealthCare Pharmaceuticals VP and head of U.S. medical affairs Pamela Cyrus said. "With the development of regorafenib and other oncology compounds, we remain committed to discovering and advancing cancer therapies for patients who are in need of new treatment options."
Amid customer complaints, Walmart cuts layaway fee
BENTONVILLE, Ark. — After announcing it would move up its layaway program for the holiday season to mid-September, Walmart said it also would reduce the program fee from $15 to $5.
"This is a direct response to feedback we received since announcing this year’s holiday layaway program," said Duncan Mac Naughton, Walmart’s chief merchandising and marketing officer. "Customers who make their final payment will receive a refund of the $5 fee on a Walmart gift card. We believe this rollback strengthens our layaway offering. It’s even more attractive to our customers and makes Walmart more competitive in the marketplace."
Other terms of Walmart’s program are comparable with last year, such as a requirement for a down payment of $10 or 10% of the purchase price, whichever is greater, but the company no longer collects a cancellation fee of $10, as was the case last year.
At Walmart, the list of merchandise categories was expanded this year after the program was reinstituted last holiday season. Walmart has added small appliances and select sporting goods such as basketball goals, trampolines and large exercise equipment to electronics, toys and jewelry as categories eligible for layaway.